VTRS · 10-Q · 2026Q3 · Full report

Acquisitions and Divestitures

Viatris Inc · 2026-11-05 · Importance 34 · Surprise 42

Viatris completed the sale of its Biocon Biologics equity position on July 14, 2026, receiving pre-tax proceeds of approximately $380 million. The transaction followed the December 2025 agreement under which Biocon acquired Viatris’ CCPS for $815 million, consisting of $400 million cash and $415 million in Biocon shares. The sale proceeds reflected a roughly 2.7% block-sale discount, transaction fees, and U.S. dollar strengthening. Viatris recorded a pre-tax loss of approximately $27.4 million in the third quarter and $36.0 million in the first nine months of 2026 from fair-value changes and the subsequent sale.

Key facts

• Viatris sold all its CCPS in Biocon Biologics for total consideration of $815 million: $400 million cash and $415 million in newly issued Biocon equity shares. source
• Viatris completed the sale of its Biocon equity position on July 14, 2026, for pretax total consideration of approximately $380 million. source
• Viatris’s biosimilars non-compete restrictions expired immediately at closing for all ex-U.S. markets and are scheduled to expire in November 2026 for the U.S. market. source
• Viatris recorded a $177.0 million charge related to the sale of the product rights for Tyrvaya® in the nine months ended September 30, 2026. source
• The Biocon Biologics transaction closed in the first quarter of 2026, and the Biocon equity shares were subject to a six-month lock-up period. source
• The Biocon equity sale proceeds reflected an approximately 2.7% block-sale discount to market, transaction fees, and U.S. dollar strengthening since Viatris obtained the equity in January 2026. source